A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells

被引:106
作者
Shuhendler, Adam J. [1 ]
Cheung, Richard Y. [1 ]
Manias, Janet [1 ]
Connor, Allegra [1 ]
Rauth, Andrew M. [2 ]
Wu, Xiao Yu [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
[2] Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Multidrug resistance; Breast cancer; Polymer-lipid hybrid nanoparticle; Combination chemotherapy; SOLID LIPID NANOPARTICLES; TOPOISOMERASE-II-ALPHA; SIMULTANEOUS DELIVERY; DRUG; CHEMOTHERAPY; COMBINATION; CYCLOPHOSPHAMIDE; CHEMOSENSITIZER; AMPLIFICATION; PACLITAXEL;
D O I
10.1007/s10549-008-0271-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anthracycline-containing treatment regimens are currently the most widely employed regimens for the management of breast cancer. These drug combinations are often designed based on non-cross resistance and minimal overlapping toxicity rather than drug synergism. Moreover, aggressive doses are normally used in chemotherapy to achieve a greater therapeutic benefit at the cost of more acute and long-term toxic effects. To increase chemotherapeutic efficacy while decreasing toxic effects, rational design of drug synergy-based regimens is needed. Our previous work showed a synergistic effect of doxorubicin (DOX) and mitomycin C (MMC) on murine breast cancer cells in vitro and improved efficacy and reduced systemic toxicity of DOX-loaded solid polymer-lipid hybrid nanoparticles (PLN) in animal models of breast cancer. Herein we have demonstrated true anticancer synergy of concurrently applied DOX and MMC, and have rationally designed PLN to effectively deliver this combination to multidrug resistant (MDR) MDA435/LCC6 human breast cancer cells. DOX-MMC co-loaded PLN were effective in killing MDR cells at 20-30-fold lower doses than the free drugs. This synergistic cell killing was correlated with enhanced induction of DNA double strand breaks that preceded apoptosis. Importantly, co-encapsulation of dual agents into a nanoparticle formulation was much more effective than concurrent application of single agent-containing PLN, demonstrating the requirement of simultaneous uptake of both drugs by the same cells to enhance the drug synergy. The rationally designed combination chemotherapeutic PLN can overcome multidrug resistance at a significantly lower dose than free drugs, exhibiting the potential to enhance chemotherapy and reduce the therapeutic limitations imposed by systemic toxicity.
引用
收藏
页码:255 / 269
页数:15
相关论文
共 41 条
[1]   ADRIAMYCIN AND MITOMYCIN-C AS INITIAL CHEMOTHERAPY FOR ADVANCED BREAST-CANCER [J].
AMIEL, SA ;
STEWART, JF ;
EARL, HM ;
KNIGHT, RK ;
RUBENS, RD .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (05) :631-634
[2]  
ANDERSSON M, 1986, CANCER TREAT REP, V70, P1181
[3]   Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer [J].
Bamias, A ;
Papamichael, D ;
Syrigos, K ;
Pavlidis, N .
JOURNAL OF CHEMOTHERAPY, 2003, 15 (03) :275-281
[4]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[5]  
Bristow R.G., 1998, Molecular and cellular basis of radiotherapy
[6]   Topoisomerase IIα gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer [J].
Buzdar, Aman J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2409-2411
[7]   Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes [J].
Calcagno, A. M. ;
Fostel, J. M. ;
To, K. K. W. ;
Salcido, C. D. ;
Martin, S. E. ;
Chewning, K. J. ;
Wu, C-P ;
Varticovski, L. ;
Bates, S. E. ;
Caplen, N. J. ;
Ambudkar, S. V. .
BRITISH JOURNAL OF CANCER, 2008, 98 (09) :1515-1524
[8]   What are the current standards of care and recent developments in the management of breast cancer? [J].
Cameron, David ;
Bell, Richard ;
Aapro, Matti ;
Zielinski, Christoph .
ONCOLOGIST, 2006, 11 :1-3
[9]   In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin [J].
Cheung, RY ;
Rauth, AM ;
Ronaldson, PT ;
Bendayan, R ;
Wu, XY .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (03) :321-331
[10]   In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations [J].
Cheung, RY ;
Rauth, AW ;
Wu, XY .
ANTI-CANCER DRUGS, 2005, 16 (04) :423-433